KRAS and colorectal carcinoma: A recent study of KRAS mutations in exons 2, 3, and 4 in stage I–IV CRC patients concluded that exon 3 mutations predict the worst prognosis, and suggested that mutations of different KRAS exons should be analyzed separately [37].